KPTIThe 0.89 level seems to function as support and could be a good basis to head towards the upper resistances, 1.17-1.40, 1.6 otherwise the collapse of this level towards new lows
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−12.4005 EUR
−73.82 M EUR
140.30 M EUR
7.91 M
About Karyopharm Therapeutics Inc.
Sector
Industry
CEO
Richard A. Paulson
Website
Headquarters
Newton
Founded
2008
ISIN
US48576U2050
FIGI
BBG00645T1N1
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.
Related stocks
KPTIthe support in area 092 holds and from here it seems to bounce towards the resistance in area 1.2 and then 1.4; otherwise the failure of the 092 area support would lead to a bearish scenario
$KPTI: Low risk buy signalNice setup in $KPTI, I suggest buying these names with small positions considering the volatility that can occur after catalysts when new data is released, or around FDA approvals, etc.
Upside can be substantial though, so if technicals and fundamentals align, it's worth keeping some exposure.
Best
KPTI - Falling WedgeFalling wedge idea for KPTI.
Areas above the arrows up are very similar hence I propose a breakout of the falling wedge is coming.
Falling wedges are considered a bullish pattern.
Bearish Bearish Divergence on the 1 hr chart. I am selling short here. Quick trade, as it is the 1 hr after all.
KPTI | LongNASDAQ:KPTI
Possible Scenario: Long
Evidence: Price Action, IH&S, Money-Flow
TP1: 7.85$
Call options, 01/21/2022, Strike 7.5$
*This is my idea and could be wrong 100%
$KPTI Target PTs 18-29 and higherAntengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma
SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicate
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Karyopharm Therapeutics, Inc. stocks are traded under the ticker 25K0.
We've gathered analysts' opinions on Karyopharm Therapeutics, Inc. future price: according to them, 25K0 price has a max estimate of 25.83 EUR and a min estimate of 5.17 EUR. Watch 25K0 chart and read a more detailed Karyopharm Therapeutics, Inc. stock forecast: see what analysts think of Karyopharm Therapeutics, Inc. and suggest that you do with its stocks.
25K0 reached its all-time high on Mar 13, 2025 with the price of 6.7080 EUR, and its all-time low was 3.1000 EUR and was reached on Aug 12, 2025. View more price dynamics on 25K0 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Karyopharm Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Karyopharm Therapeutics, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
25K0 earnings for the last quarter are −3.67 EUR per share, whereas the estimation was −3.46 EUR resulting in a −5.84% surprise. The estimated earnings for the next quarter are −2.95 EUR per share. See more details about Karyopharm Therapeutics, Inc. earnings.
Karyopharm Therapeutics, Inc. revenue for the last quarter amounts to 32.20 M EUR, despite the estimated figure of 32.29 M EUR. In the next quarter, revenue is expected to reach 35.85 M EUR.
25K0 net income for the last quarter is −31.62 M EUR, while the quarter before that showed −21.69 M EUR of net income which accounts for −45.82% change. Track more Karyopharm Therapeutics, Inc. financial stats to get the full picture.
No, 25K0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 18, 2025, the company has 279 employees. See our rating of the largest employees — is Karyopharm Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Karyopharm Therapeutics, Inc. EBITDA is −97.53 M EUR, and current EBITDA margin is −82.01%. See more stats in Karyopharm Therapeutics, Inc. financial statements.
Like other stocks, 25K0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Karyopharm Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.